Where does IMBA—INSTITUT FÜR Molekulare Biotechnologie GMBH rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), IMBA—INSTITUT FÜR Molekulare Biotechnologie GMBH ranks #29,055 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does IMBA—INSTITUT FÜR Molekulare Biotechnologie GMBH hold?

IMBA—INSTITUT FÜR Molekulare Biotechnologie GMBH holds 9 US utility patents granted between 2016 and 2024, spanning 7 technology areas.

What is IMBA—INSTITUT FÜR Molekulare Biotechnologie GMBH's Innovation Score?

IMBA—INSTITUT FÜR Molekulare Biotechnologie GMBH has an Innovation Score of 47.4 out of 100 (top 19% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is IMBA—INSTITUT FÜR Molekulare Biotechnologie GMBH's patent grant rate increasing or decreasing?

IMBA—INSTITUT FÜR Molekulare Biotechnologie GMBH's recent grant velocity is +25% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for IMBA—INSTITUT FÜR Molekulare Biotechnologie GMBH's patents?

IMBA—INSTITUT FÜR Molekulare Biotechnologie GMBH's patents average 16.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

IMBA—INSTITUT FÜR Molekulare Biotechnologie GMBH

Q: What technology areas does IMBA—INSTITUT FÜR Molekulare Biotechnologie GMBH focus on?

IMBA—INSTITUT FÜR Molekulare Biotechnologie GMBH's top technology area is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media) with 8 patents, ranking #1,253 of 4,144 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

Q: How is the IMBA—INSTITUT FÜR Molekulare Biotechnologie GMBH patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO PatentsView assignee record - 9 granted patents across 7 technology areas, recorded in grant years 2016–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Imba—institut ranks #29,055 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 7 technology areas.

#29,055
of 49,997 US assignees by volume: Top 19%
by Innovation Score (47.4/100): 16.9
avg claims per patent: +25%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R29055 · Foreign Corporation #29,055 · 9 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-UP · BOOK-FULL

GRANTS-MICRO 9 grants
MID-PACK #29,055/49,997
PHOTO-FINISH Ihara Science
CPC-NARROW C12N · 7 areas
INNOV-PAR 47.4/100
CLAIMS-RICH 16.9 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-UP +25% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Ihara Science Corporation (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Imba—institut’s 47.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.0 pts (17%) Velocity 20.0 pts (42%) Breadth 9.4 pts (20%) Claim depth 10.1 pts (21%)

Qualcomm Incorporated · highest

85
Everseen · near

47
IMBA—INSTITUT FÜR… · this assignee

47
National University… · near

47
Ontario Institute… · near

47
UMC Utrecht Holding… · near

47
3D Lighting… · lowest

7

What this shows Imba—institut's Innovation Score is 47.4/100 (top 19% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Imba—institut?

Each dot is one of Imba—institut’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Imba—institut’s own 16.9 claims/patent is ABOVE the 12.2 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Imba—institut vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Imba—institut's grants concentrate

IMBA—INSTITUT FÜR Molekulare Biotechnologie GMBH is a focused PatentsView assignee: 7 CPC subclasses with 88.9% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2024 (4 grants) versus a trough of 1 in 2018. By volume, Imba—institut sits between Ihara Science Corporation and Impac Medical Systems, Inc..

Imba—institut's three-year grant acceleration

IMBA—INSTITUT FÜR Molekulare Biotechnologie GMBH shows 5 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Ihara Science

9
Ii-vi Advanced Ma…

9
Iljin Electric

9
Imaginalis S R L

9
Imedicom

9
Immuneonco Biopha…

9
Immunoqure

9
Impac Medical Sys…

9
IMBA—Institut FÜR… ◀

9

What this shows IMBA—INSTITUT holds 9 patents at rank #29,035, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near IMBA—INSTITUT

By rank, the assignees closest to #29,035 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in IMBA—INSTITUT's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for IMBA—INSTITUT, neither rank-band nor same-CPC leaders (those blocks stay above). In C12N (Microorganisms OR Enzymes), IMBA—INSTITUT ranks #1,253 of 4,144 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (47 here).

Ontario Institute for Cancer Research (OICR) 47 Everseen Limited 47 National University Corporation Nara Institute OF Science AND Technology 47 UMC Utrecht Holding B.V. 47

Imba—institut's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

47 Top 19% higher than 81% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

IMBA—INSTITUT FÜR Molekulare Biotechnologie GMBH patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	2	22.2%
2018	1	11.1%
2019	1	11.1%
2022	1	11.1%
2024	4	44.4%

Which technologies does IMBA—INSTITUT FÜR Molekulare Biotechnologie GMBH patent most?

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 8

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 4

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 3

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 3

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 1

C07K - Peptides 1

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 1

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

IMBA—INSTITUT FÜR Molekulare Biotechnologie GMBH's patent record in context - here's where to go next.

IMBA—INSTITUT FÜR Molekulare Biotechnologie GMBH's lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 88.9% of its portfolio - see every assignee active in that class. Explore C12N
Ranked #29,055 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare IMBA—INSTITUT FÜR Molekulare Biotechnologie GMBH against Ihara Science Corporation, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 47.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.